Occipital bone

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
tisdag, juli 11, 2023
Research, Other Health, General Health, Pharmaceutical, Biometrics, Mental Health, Clinical Trials, Science, Neurology, Biotechnology, FDA, Health, Other Science, Genotype, Atrophy, MH, Cerebral amyloid angiopathy, CAA, Prevalence, Pathology, NDA, Black box, COVID, Siderosis, Biomarker, MCI, Doctor of Philosophy, Female, Mild, Common, Blood, Plasma, MRI, Alzheimer's disease, ARIA, Occipital bone, Magnetic resonance imaging, Cortex, MD, Patient, Risk, Horseshoe kidney, CEST, Lateral ventricles, Composite, Medicine, Drug development, Oral, AD, Cerebral edema, MMSE, Conference, Neurotoxicity, Safety, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon, Early

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Retrieved on: 
tisdag, april 18, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Mitt, MH, CAA, Cerebral amyloid angiopathy, Cerebral edema, AAN, Pathology, NDA, American Academy, EST, COVID, Siderosis, Inflammation, MCI, Doctor of Philosophy, Neurotoxicity, Common, Blood, Biomarker, Plasma, ARIA, Occipital bone, Amyloid, MD, ADNI, Patient, Risk, Composite, Prevalence, Oral, Microglia, AD, Safety, MMSE, Conference, Female, American Academy of Neurology, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in mid-2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

HAVENLY DEBUTS FIRST NEW YORK CITY POP-UP SHOWROOM AND DESIGN CENTER

Retrieved on: 
måndag, juli 18, 2022
Creative visualization (design), Acquisition, Book club, Occipital bone, Creative, App Store (iOS/iPadOS), The Inside, AM, Budget, Growth, Partnership, Spring Street (Manhattan), New Yorkers, Interior design, Inside

DENVER, July 18, 2022 /PRNewswire/ -- Havenly, the largest nationwide interior design business, announced today the opening of their first ever New York pop-up showroom and design center. New Yorkers will be able to visit the Havenly showroom to see exclusive collections, purchase decor items, and experience Havenly's newly launched in-person design services with Havenly expert designers. Experiencing significant growth, including a national expansion to in-person design, the acquisition of fast growing direct-to-consumer home furnishings brand The Inside, the announcement of a multi-year partnership with Reese's Book Club, and the purchase of 3D layout and visualization technology from spatial computing company Occipital, Havenly is excited to continue to expand its fresh perspective on interior design into a retail experience.

Key Points: 
  • DENVER, July 18, 2022 /PRNewswire/ -- Havenly ,the largest nationwide interior design business, announced today the opening of their first ever New York pop-up showroom and design center.
  • New Yorkers will be able to visit the Havenly showroom to see exclusive collections, purchase decor items, and experience Havenly's newly launched in-person design services with Havenly expert designers.
  • Unlike traditional design, which prioritizes high-end luxury projects, cherry-picks favorable client design styles, and requires huge budgets, Havenly offers its unique services, designed for any budget, room or design style, to everyone.
  • ft. pop-up in Nolita is designed by a team of Havenly interior design experts led by Vice President of Creative and Design, Shelby Girard.

HAVENLY ANNOUNCES NATIONAL EXPANSION OF IN-PERSON DESIGN SERVICES

Retrieved on: 
onsdag, maj 4, 2022
Name, Culture, Frustration, Generation Z, Budget, Millennials, Acquisition, App Store (iOS/iPadOS), Mental health, CEO, Technology, Entrepreneurship, 3D, Work, Interior design, Online shopping, Inside, Occipital bone

DENVER, May 4, 2022 /PRNewswire/ -- Havenly, the largest nationwide interior design business, announced today it is expanding into in-person design services, building on its mission to become the destination for inclusive and accessible interior design and furnishings.

Key Points: 
  • DENVER, May 4, 2022 /PRNewswire/ -- Havenly ,the largest nationwide interior design business, announced today it is expanding into in-person design services, building on its mission to become the destination for inclusive and accessible interior design and furnishings.
  • By creating an entry point for design with this unique demographic, Havenly's program introduces more customers to the transformative power of interior design and ultimately creates a longstanding pipeline for traditional interior design services.
  • Havenly's in-person interior design services are now available for early access pricing of $499 ($200 off) for the first room design and $199 for each additional room, a fraction of the price of typical interior design services.
  • Havenly is the largest interior design service that makes expert design accessibleto anyone, regardless of budget or location.

INTERIOR DESIGN COMPANY HAVENLY ACQUIRES THE INSIDE

Retrieved on: 
torsdag, februari 17, 2022
Book club, Acquisition, App Store (iOS/iPadOS), Growth, The Inside, Name, Marriage, CEO, Partnership, Entrepreneurship, Technology, Retail, Occipital bone, Inside

DENVER, Feb. 17, 2022 /PRNewswire/ -- Havenly ,the largest online interior design service, announced today it has acquired The Inside , a direct-to-consumer home furnishings brand that has grown nearly 600% in the past two years.

Key Points: 
  • DENVER, Feb. 17, 2022 /PRNewswire/ -- Havenly ,the largest online interior design service, announced today it has acquired The Inside , a direct-to-consumer home furnishings brand that has grown nearly 600% in the past two years.
  • Under the terms of the deal, Havenly has acquired the key assets of The Inside, inclusive of its intellectual property and inventory.
  • The Inside Co-Founder Danielle Walish will join Havenly to manage the transition, integrate The Inside assets into Havenly, and capitalize on the shift in consumer design trends favoring prints offered by The Inside.
  • Havenly is the largest online interior design service that makes expert design accessibleto anyone, regardless of budget or location.

EQS-News: Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Retrieved on: 
måndag, december 20, 2021
Stand Alone, AOU, Solution, FDA, Education, Spine, Anatomical terms of location, Occipital bone, Trauma, Deformity, Adoption, Risk, Safety, Patient, 3D, CT, Degenerative disc disease, Pathology, Neoplasm, Medicine, Spinal fusion, Surgeon, Anatomy, Mini, ACDF, OR, Birth control, Medical device, Medical imaging, Dentistry

Medacta Launches 360 (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Key Points: 
  • Medacta Launches 360 (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem
    Medacta Launches 360(Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem
    CASTEL SAN PIETRO, Switzerland, December 14, 2021 - Medacta is further demonstrating its commitment to innovation and personalized solutions by offering an end-to-end 360 cervical platform featuring ease-of-use, improved flexibility, stability[1] and accuracy[1] for posterior fixation and anterior cervical discectomy and fusion (ACDF).
  • "With the new 360 cervical platform, Medacta supports surgeons to treat the cervical spine both from the anterior and posterior approaches," says Francesco Siccardi, Chief Executive Officer of Medacta.
  • "The Medacta cervical platform features a range of high-level technologies that work together to provide versatility to surgeons and safety to patients.
  • This is a clear step forward towards our goal of developing highly personalized surgical solutions," concludes Siccardi.